SCHEMBL22112764

SCHEMBL22112764

O=S(=O)(c1ccccc1)n1cc(Br)c(Br)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARL Q9H300 1/20 0.48
PKM P14618 2/20 0.47
CA1 P00915 3/20 0.44
CA2 P00918 3/20 0.44
CA4 P22748 2/20 0.44
CA6 P23280 2/20 0.44
CA12 O43570 1/20 0.44
CA3 P07451 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
PLA2G7 Q13093 1/20 0.44
CA9 Q16790 1/20 0.44
CA13 Q8N1Q1 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
CYP2C9 P11712 3/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2C19 P33261 2/20 0.44
MMP2 P08253 1/20 0.44
CYP2D6 P10635 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1076218 0.78 PKM (0.56) PARLPKMCA1CA2CYP2C9
SCHEMBL752816 0.75 CA1 (0.65) PARLPKMCA1CA2CA4
SCHEMBL28053766 0.71 PKM (0.57) PARLPKMCA1CA2CYP2C9
SCHEMBL1996382 0.70 HTR6 (0.64) CA1CA2CA12CA9HTR6
SCHEMBL12546389 0.70 L3MBTL1 (0.46) PARLPKMCYP2C9CYP3A4CYP2C19
SCHEMBL12569759 0.69 PKM (0.60) PARLPKMCA1CA2CYP2C9
SCHEMBL1647468 0.69 PKM (0.56) PARLPKMCA1CA2CA4
SCHEMBL28195638 0.69 PKM (0.56) PARLPKMHTR6MAPTPOLB
SCHEMBL4614396 0.69 PKM (0.56) PARLPKMCA1CA2CYP2C9
SCHEMBL12674582 0.69 KLKB1 (0.51) PARLPKMCA1CA2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020123994-A1 2-((5-(PHENYL)-PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)AMINO)-3-(PHENYL)PROPANOIC ACID DERIVATIVES AND RELATED COMPOUNDS AS MCL-1 ENZYME INHIBITORS FOR TREATING CANCER PRELUDE THERAPEUTICS, INCORPORATED (US) 2020-06-18 WO disclosed